Drug intelligence / Profile preview

vonoprazan + amoxicillin + tripotassium dicitrate bismuthate

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

This appears to be a combination of vonoprazan (a potassium-competitive acid blocker), amoxicillin (an antibiotic), and tripotassium dicitrate bismuthate (a bismuth salt). However, based on the search results, this specific triple combination is not documented as a single formulation. The search results discuss vonoprazan-amoxicillin dual therapy compared to bismuth-containing quadruple therapy as separate treatment approaches for Helicobacter pylori infection.

Other names
Bismuth/Amoxicillin/PCAB Triple TherapyBismuth amoxicillin potassiumBismuth amoxilillin potassiumBismuth + amoxicillin potassium-Kaohsiung Medical University-Helicobacter pylori infection
02

Targets

PBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on vonoprazan + amoxicillin + tripotassium dicitrate bismuthate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vonoprazan + amoxicillin + tripotassium dicitrate bismuthate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call